Cargando…

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer

Preclinical studies of PD-L1 and CTLA-4 blockade have relied heavily on mouse syngeneic tumor models with intact immune systems, which facilitate dissection of immunosuppressive mechanisms in the tumor microenvironment. Commercially developed monoclonal antibodies (mAbs) targeting human PD-L1, PD-1,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schofield, Darren J., Percival-Alwyn, Jennifer, Rytelewski, Mateusz, Hood, John, Rothstein, Raymond, Wetzel, Leslie, McGlinchey, Kelly, Adjei, Grace, Watkins, Amanda, Machiesky, LeeAnn, Chen, Weimin, Andrews, John, Groves, Maria, Morrow, Michelle, Stewart, Ross A., Leinster, Andrew, Wilkinson, Robert W., Hammond, Scott A., Luheshi, Nadia, Dobson, Claire, Oberst, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831362/ https://www.ncbi.nlm.nih.gov/pubmed/33397194 http://dx.doi.org/10.1080/19420862.2020.1857100

Ejemplares similares

Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2022)

Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2020)

An Uncommon Case of Myocarditis Secondary to Durvalumab Plus Tremelimumab
por: Diaz-Rodriguez, Porfirio E, et al.
Publicado: (2023)

Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
por: Arru, Caterina, et al.
Publicado: (2021)

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
por: Alt, Marie, et al.
Publicado: (2023)

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
por: Song, Xuyang, et al.
Publicado: (2023)

A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer
por: Santa-Maria, Cesar August, et al.
Publicado: (2018)

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
por: Capdevila, J., et al.
Publicado: (2023)

Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR
por: Gilbert, Jill, et al.
Publicado: (2015)

Adverse Events and Tolerability of Combined Durvalumab and Tremelimumab versus Durvalumab Alone in Solid Cancers: A Systematic Review and Meta-Analysis
por: Fahmy, Omar, et al.
Publicado: (2022)

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
por: Hamid, Omid, et al.
Publicado: (2023)

Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report
por: Mahmood, Syed S., et al.
Publicado: (2018)

Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma
por: Lee, Dae Ho, et al.
Publicado: (2023)

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract
por: Sarfaty, Michal, et al.
Publicado: (2020)

Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07
por: Kim, Miso, et al.
Publicado: (2020)

Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis
por: Matsumoto, Hiromi, et al.
Publicado: (2023)

Progressive hypoventilation due to mixed CD8(+) and CD4(+) lymphocytic polymyositis following tremelimumab - durvalumab treatment
por: John, Sooraj, et al.
Publicado: (2017)

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
por: Bahig, Houda, et al.
Publicado: (2019)

Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma
por: Cheng, Li, et al.
Publicado: (2021)

Tremelimumab
Publicado: (2012)

Early circulating tumor DNA dynamics as a pan‐tumor biomarker for long‐term clinical outcome in patients treated with durvalumab and tremelimumab
por: Kansara, Maya, et al.
Publicado: (2022)

Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial
por: Ogasawara, Sadahisa, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wildsmith, Sophie, et al.
Publicado: (2023)

Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Kim, Hana, et al.
Publicado: (2023)

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
por: Thibaudin, Marion, et al.
Publicado: (2023)

A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors
por: Papadopoulos, Kyriakos P, et al.
Publicado: (2015)

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
por: Pakkala, Suchita, et al.
Publicado: (2020)

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
por: Kelley, Robin Kate, et al.
Publicado: (2021)

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer
por: Doki, Yuichiro, et al.
Publicado: (2022)

Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
por: Rubinstein, Maria M., et al.
Publicado: (2023)

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab
por: Dey, Agnish, et al.
Publicado: (2022)

Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC
por: Rizvi, Naiyer, et al.
Publicado: (2015)

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
por: Renouf, Daniel J., et al.
Publicado: (2022)

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
por: Johnson, Melissa L., et al.
Publicado: (2023)

Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8
por: Hecht, Markus, et al.
Publicado: (2020)

Tremelimumab: research and clinical development
por: Comin-Anduix, Begoña, et al.
Publicado: (2016)

Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
por: Ferris, Robert L, et al.
Publicado: (2015)

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
por: Kelly, Ronan J, et al.
Publicado: (2015)

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
por: Rizvi, Naiyer A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_onvainpvsnecuhjq0a57671hk0